| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 6 | | | |
| ||||||||
| | | | 17 | | | ||
| | | | | 19 | | | |
| | | | | 25 | | | |
| | | | | ||||
| | |||||||
| | | | | | | ||
| | | | | 26 | | |
Name | | | Age | | | Position | | | Date Appointed | |
Nevan Charles Elam | | | | | Chief Executive Officer, Principal Financial Officer and Acting Chairman of the Board | | | January 31, 2013 | | |
Gil Labrucherie | | | | | Director | | | November 20, 2019 | | |
Nerissa Kreher | | | 50 | | | Director | | | March 2, 2021 | |
Philippe Fauchet | | | | | Director | | | September 10, 2020 | | |
| | | | Director | | | March 2, 2021 | | ||
| | | | Director | | | |
Total Number of Directors | | 6 | | ||||||||||||||||||||||||
| Total Number of Directors | | 6 | | | Male | | Female | | ||||||||||||||||||
| | | | | Male | | | | | Female | | | |||||||||||||||
| Part I: Gender Identity | | | | | | | | | | | | |||||||||||||||
| Directors | | | | 5 | | | | | 1 | | | |||||||||||||||
| Part II: Demographic Background | | | | | | | | | | | | |||||||||||||||
��� | White | | | | 3 | | | | | 1 | | | |||||||||||||||
| Did Not Disclose Demographic Background | | | | 0 | | | | | 0 | | | |||||||||||||||
| Directors who are Military Veterans: | | | | 1 | | | | | 0 | | | |||||||||||||||
| Directors with Disability: | | | | 0 | | | | | 0 | | | |||||||||||||||
Part I: Gender Identity | | | | | | | | | | | | ||||||||||||||||
Directors | | | | 5 | | | | | 1 | | | ||||||||||||||||
Part II: Demographic Background | | | | | | | | | | | | ||||||||||||||||
White | | | | 3 | | | | | 1 | | | ||||||||||||||||
African American or Black | | | | 1 | | | | | — | | | ||||||||||||||||
Asian | | | | 1 | | | | | — | | | ||||||||||||||||
Did Not Disclose Demographic Background | | | | — | | | | | — | | | ||||||||||||||||
Directors who are Military Veterans | | | | 1 | | | | | — | | |
| | | Committee Appointments | | ||||||
Director Name | | | Audit | | | Compensation | | | Nominating and Governance | |
Committee Members as of June 30, 2022: | | | | | | | | | | |
Gil Labrucherie(1) | | | X | | | X | | | X | |
Nerissa Kreher(2) | | | | | | X | | | X | |
Philippe Fauchet(3) | | | X | | | X | | | X | |
Wladimir Hogenhuis(4) | | | X | | | X | | | X | |
Name | | | Fees Earned or Paid in Cash ($) | | | Option Awards ($) | | | Total ($) | | |||||||||
Gil Labrucherie | | | | | | | | | | ||||||||||
| | | | | | | |||||||||||||
Nerissa Kreher | | | | | 47,000 | | | | | | | | | | | 258,168 | | | |
Phillippe Fauchet | | | | | 57,000(3) | | | | | | 211,168(7) | | | | | | 268,168 | | |
Wladimir Hogenhuis | | | | | | | | | | | | | | | | | |||
| | | | | | | | | | | | | | | |
| | | Shares Underlying Options outstanding | | |||||||||
| | | Vested | | | Unvested | | ||||||
Gil Labrucherie | | | | | 4,222 | | | | | | 8,778 | | |
Philippe Fauchet | | | | | 2,000 | | | | | | 8,000 | | |
Wladimir Hogenhuis | | | | | — | | | | | | 10,000 | | |
Nerissa Kreher | | | | | — | | | | | | 10,000 | | |
| | | Shares Underlying Options Outstanding | | |||||||||
| | | Vested | | | Unvested | | ||||||
Gil Labrucherie | | | | | 8,554 | | | | | | 84,446 | | |
Philippe Fauchet | | | | | 5,110 | | | | | | 84,890 | | |
Wladimir Hogenhuis | | | | | 3,333 | | | | | | 86,667 | | |
Nerissa Kreher | | | | | 3,333 | | | | | | 86,667 | | |
Young-Jin Kim | | | | | — | | | | | | 40,000 | | |
Name of Beneficial Owner | | | Position with Company | | | Beneficial Ownership | | | Percent of Class | | ||||||
Stockholders in excess of 5% | | | | | | | | | | | | | | | | |
Entities associated with Federated Hermes, Inc. | | | Stockholder | | | | | | | | | | 19.9% | | | |
Handok Inc. | | | Stockholder | | | | | | | | | | | | ||
| | Stockholder | | | | | | | | | | | | |||
Stonepine Capital, L.P. | | | Stockholder | | | | | | | | | | | | ||
Directors and Executive | | | | | | | | | | | | | | | | |
Nevan Charles Elam | | | Chief Executive Officer and Acting Chairman of the Board | | | | | | | | | | ||||
| | |||||||||||||||
Gil Labrucherie | | | Director | | | | | | | | | | * | | | |
Philippe Fauchet | | | Director | | | | | | | | | | * | | | |
Nerissa Kreher | | | Director | | | | | 33,332(8) | | | | | | * | | |
Wladimir Hogenhuis | | | Director | | | | | | | | | | * | | | |
| | Director | | | | | | | | | | | | |||
Brian Roberts | | | | | | | | | | | | * | | | ||
Directors and executive officers as a group (7 people) | | | | | | | | | | | | | | |
| | | FISCAL 2021 | | | FISCAL 2020 | | ||||||
Audit fees(1) | | | | $ | 175,500 | | | | | $ | 142,000 | | |
Tax fees(2) | | | | | 38,100 | | | | | | 12,000 | | |
Total | | | | $ | 213,600 | | | | | $ | 154,000 | | |
| | | Plan Termination Date | | | Shares to be Issued Upon Exercise of Outstanding Options: | | | Securities Available For Future Issuance | | | ||||||||||||||
| Number of Shares | | | Weighted Average Exercise Price | | | |||||||||||||||||||
Equity compensation plans approved by security holders: | | | | | | | | | | | | | | | | | | | | | | | | ||
2015 Non-Qualified Stock Option Plan | | | February 23, 2020 | | | | | 36 | | | | | $ | 50.73 | | | | | | — | | | | ||
2016 Non-Qualified Stock Option Plan | | | October 31, 2021 | | | | | 256 | | | | | | 22.77 | | | | | | — | | | | ||
2021 Equity Incentive Plan | | | March 31, 2031 | | | | | 8,014 | | | | | | 4.24 | | | | | | 2,686 | | | | ||
Equity compensation plans not approved by security holders: | | | | | | | | | | | | | | | | | | | | | | | | ||
2019 Non Qualified Stock Option Plan | | | July 31, 2029 | | | | | 200 | | | | | | 14.50 | | | | | | — | | | | ||
Total | | | | | | | | 8,506 | | | | | | 5.24 | | | | | | 2,686 | | | | | |
| | | | | | As of May 5, 2022 | | | As of June 30, 2021 | | ||||||||||||||||||||||||||||||
| Plan Termination Date | | | Shares to be Issued Upon Exercise of Outstanding Options: | | | Securities Available For Future Issuance | | | Shares to be Issued Upon Exercise of Outstanding Options: | | | Securities Available For Future Issuance | | ||||||||||||||||||||||||||
| Number of Shares | | | Weighted Average Exercise Price | | | Number of Shares | | | Weighted Average Exercise Price | | |||||||||||||||||||||||||||||
Equity compensation plans approved by security holders: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
2014 Stock and Incentive Plan | | | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,999 | | | | | $ | 92.05 | | | | | | — | | |
2015 Non-Qualified Stock Option Plan | | | February 23, 2020 | | | | | 36,400 | | | | | $ | 50.73 | | | | | | — | | | | | | 50,900 | | | | | | 40.85 | | | | | | — | | |
2016 Non-Qualified Stock Option Plan | | | October 31, 2021 | | | | | 260,400 | | | | | | 22.63 | | | | | | — | | | | | | 326,612 | | | | | | 21.98 | | | | | | — | | |
2021 Equity Incentive Plan | | | March 31, 2030 | | | | | 1,079,766 | | | | | | 9.71 | | | | | | 120,234 | | | | | | 705,000 | | | | | | 12.28 | | | | | | 495,000 | | |
Equity compensation plans not approved by security holders: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
2019 Non Qualified Stock Option Plan | | | July 31, 2029 | | | | | 200,000 | | | | | | 14.50 | | | | | | — | | | | | | 200,000 | | | | | | 14.50 | | | | | | — | | |
| | | | | | As of May 5, 2022 | | | As of June 30, 2021 | | ||||||||||||||||||||||||||||||
| Plan Termination Date | | | Shares to be Issued Upon Exercise of Outstanding Options: | | | Securities Available For Future Issuance | | | Shares to be Issued Upon Exercise of Outstanding Options: | | | Securities Available For Future Issuance | | ||||||||||||||||||||||||||
| Number of Shares | | | Weighted Average Exercise Price | | | Number of Shares | | | Weighted Average Exercise Price | | |||||||||||||||||||||||||||||
Total | | | | | | | | 1,576,566 | | | | | | 13.40 | | | | | | 120,234 | | | | | | 1,284,511 | | | | | | 16.35 | | | | | | 495,000 | | |
|
| | | 2022 | | | 2021 | | ||||||||||||||||||
| | | Amount | | | Percent | | | Amount | | | Percent | | ||||||||||||
Audit fees(1) | | | | $ | 259,000 | | | | | | 85% | | | | | $ | 175,500 | | | | | | 82% | | |
Tax fees | | | | | 47,225 | | | | | | 15% | | | | | | 38,100 | | | | | | 18% | | |
Total | | | | $ | 306,225 | | | | | | 100% | | | | | $ | 213,600 | | | | | | 100% | | |
Name | | | Age | | | Position | | | Date Appointed | |
Nevan Charles Elam | | | | | Chief Executive Officer, Principal Financial Officer and Acting Chairman of the Board | | | January 31, 2013 | | |
Brian Roberts | | | | | | | |
Name and Position | | | Fiscal Year | | | Salary | | | Bonus | | | Stock Option Awards | | | All Other Compensation | | | Total | | ||||||||||||||||||
Nevan Elam, | | | | | 2021 | | | | | $ | 495,682(1) | | | | | $ | 490,980(4) | | | | | $ | 3,888,117(6) | | | | | $ | 21,953(7) | | | | | $ | 4,896,732 | | |
Chief Executive Officer | | | | | 2020 | | | | | $ | 490,000(1) | | | | | $ | 97,020(5) | | | | | $ | 2,688,000(6) | | | | | $ | 23,683(7) | | | | | $ | 3,298,703 | | |
Brian Roberts | | | | | 2021 | | | | | $ | 371,364(2) | | | | | $ | 171,300(4) | | | | | $ | 775,203(6) | | | | | $ | 36,074(8) | | | | | $ | 1,353,941 | | |
SVP, Clinical Development | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Keith Vendola, | | | | | 2021 | | | | | $ | 244,716(3) | | | | | $ | 166,440(4) | | | | | $ | — | | | | | $ | 206,902(9) | | | | | $ | 618,058 | | |
Former Chief Financial Officer | | | | | 2020 | | | | | $ | 365,000(3) | | | | | $ | 36,135(5) | | | | | $ | 538,000(6) | | | | | $ | 13,581(9) | | | | | $ | 952,716 | | |
Name and Position | | | Fiscal Year | | | Salary | | | Bonus | | | Stock Option Awards | | | All Other Compensation | | | Total | | |||||||||||||||
Nevan Charles Elam | | | 2022 | | | | $ | 515,000(1) | | | | | $ | 378,750(3) | | | | | $ | 6,862,960(5) | | | | | $ | 24,590(6) | | | | | $ | 7,781,300 | | |
Chief Executive Officer | | | 2021 | | | | $ | 495,682(1) | | | | | $ | 490,980(4) | | | | | $ | 3,888,117(5) | | | | | $ | 21,953(6) | | | | | $ | 4,896,732 | | |
Brian Roberts, M.D. | | | 2022 | | | | $ | 401,500(2) | | | | | $ | 121,875(3) | | | | | $ | 1,847,720(5) | | | | | $ | 52,053(7) | | | | | $ | 2,423,148 | | |
Chief Medical Officer | | | 2021 | | | | $ | 371,364(2) | | | | | $ | 171,300(4) | | | | | $ | 775,203(5) | | | | | $ | 36,074(8) | | | | | $ | 1,353,941 | | |
Name | | Grant Date | | | Number of Securities Underlying Unexercised Options | | | Option Exercise Price | | Option Expiration Date | | |||||||||||||||||||||||||||||||||||||||||||||
| Exercisable | | Unexercisable | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Nevan Charles Elam | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||
| | | Grant Date | | | Number of Securities Underlying Unexercised Options | | | Option Exercise Price | | Option Expiration Date | | | 7/31/19 | | | | 195,833 | | | | | 4,167(1) | | | | $ | 14.50 | | | 7/31/29 | | ||||||||||||||||||||||||
Name | | Exercisable | | Unexercisable | | |||||||||||||||||||||||||||||||||||||||||||||||||||
Nevan C. Elam | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||
| | | | 7/31/19 | | | | | 145,833 | | | | | 54,167(1) | | | | $ | 14.50 | | | | | 7/31/29 | | | | 6/14/21 | | | | 125,000 | | | | | 250,000(2) | | | | | 12.28 | | | 6/14/31 | | ||||||||||
| | | | 6/14/21 | | | | | — | | | | | 375,000(2) | | | | | 12.28 | | | | | 6/14/31 | | | | 6/23/22 | | | | — | | | | | 2,600,000(4) | | | | | 3.40 | | | 6/23/32 | | ||||||||||
Total for Mr. Elam | | | | | | | | | 145,833 | | | | | 429,167 | | | | | | | | | | | | | | | | | | 320,833 | | | | | 2,854,167 | | | | | | | | | | ||||||||||
Brian Roberts | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||
Brian Roberts, M.D. | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||
| | | | 7/31/19 | | | | | 29,167 | | | | | 10,833(1) | | | | $ | 14.50 | | | | | 7/31/29 | | | | 7/31/19 | | | | 39,166 | | | | | 834(1) | | | | $ | 14.50 | | | 7/31/29 | | ||||||||||
| | | | 6/14/21 | | | | | 18,750 | | | | | 56,250(3) | | | | | 12.28 | | | | | 6/14/31 | | | | 6/14/21 | | | | 37,500 | | | | | 37,500(3) | | | | | 12.28 | | | 6/14/31 | | ||||||||||
Total for Mr. Roberts | | | | | | | | | 47,917 | | | | | 67,083 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||
Keith Vendola(4) | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||
| | | | 7/2/18 | | | | | 14,583 | | | | | 833 | | | | $ | 25.50 | | | | | 7/2/28 | | | | 6/23/22 | | | | — | | | | | 700,000(4) | | | | | 3.40 | | | 6/23/32 | | ||||||||||
| | | | 7/31/19 | | | | | 29,167 | | | | | 1,667 | | | | | 14.50 | | | | | 7/31/29 | | | ||||||||||||||||||||||||||||||
Total for Mr. Vendola | | | | | | | | | 43,750 | | | | | 2,500 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||
Total for Dr. Roberts | | | | | | 76,666 | | | | | 738,334 | | | | | | | | | |